FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of pharmaceutics, namely, deals with compounds of formula
, suitable for reduction of regulation of biological activity of melanocortin-5 receptor (MC5R). Such diseases and/or conditions include, but are not limited by, acne, seborrhoea, seborrheic dermatitis, cancer and inflammatory diseases.
EFFECT: compounds of claimed invention can be applied for treatment of diseases and/or conditions, in which reducing regulation of MC5R is favourable.
3 cl, 109 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | 2009 |
|
RU2530017C2 |
| 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE ANTAGONISTS OF MELANOCORTIN 5-RECEPTOR | 2009 |
|
RU2524245C2 |
| LIGANDS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2277535C2 |
| DERIVATIVES OF DOLAPROIN-DOLAIZOLEIN PEPTIDES | 2015 |
|
RU2747989C2 |
| SERINE PROTEASE INHIBITORS | 1997 |
|
RU2172321C2 |
| MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
| AMIDE DERIVATIVES | 2004 |
|
RU2375352C2 |
| V1A-RECEPTORS AGONISTS | 2013 |
|
RU2634617C2 |
| RGD-CONTAINING PEPTIDES | 2001 |
|
RU2214416C2 |
| PEPTIDES, METHOD OF THEIR SYNTHESIS, AGENT SHOWING BRADYKININ-ANTAGONISTIC ACTIVITY | 1993 |
|
RU2109747C1 |
Authors
Dates
2015-07-10—Published
2009-02-27—Filed